iCad (NSDQ:ICAD) today announced that it has appointed Stacey Stevens as president and CEO, effective March 1, 2022.

Stevens has served as the Nashua, N.H.-based company’s president since 2019. She succeeds chairperson and CEO Michael Klein, who will continue to serve as chairperson of iCad’s board of directors.

“We are currently at an important inflection point, with the recent launch of several first-in-kind technologies and the Company’s increasing focus on enterprise sales on the Detection side of the business, and with the expansion of Xoft in emerging applications, such as the treatment of brain tumors, on the Therapy side of the business,” Klein said in a news release. “I am confident that with Ms. Stevens at the helm, iCad and its technologies will continue to transform the landscape of cancer detection and therapy and accelerate the value we bring to all of our stakeholders.”

Prior to becoming iCad’s president in 2019, Stevens served as the executive VP and chief strategy and commercial officer since 2017 but joined the company in 2006 as senior VP of marketing and strategy. She has held numerous commercial leadership positions in the medtech industry, including multiple business units at Philips Healthcare.